Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 4/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.41 |
| ▸ | PTK6 | Q13882 | 6/20 | 0.39 |
| ▸ | CCR2 | P41597 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CBLB | Q13191 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30581371 | 0.90 | GRM1 (0.46) | GRM1GRM4PTK6NAMPTTP53 | |
| SCHEMBL30098796 | 0.86 | GRM1 (0.47) | GRM1GRM4PTK6CCR2KCNH2 | |
| SCHEMBL30581367 | 0.84 | GRM1 (0.48) | GRM1GRM4PTK6CCR2KCNH2 | |
| SCHEMBL29763550 | 0.83 | GRM1 (0.52) | GRM1GRM4PTK6NAMPTCBLB | |
| SCHEMBL23692963 | 0.81 | PTK6 (0.34) | PTK6TP53MAPTSMN1; SMN2 | |
| SCHEMBL23693442 | 0.81 | PTK6 (0.34) | PTK6TP53MAPTSMN1; SMN2 | |
| SCHEMBL24707042 | 0.80 | PTK6 (0.34) | PTK6TP53MAPT | |
| SCHEMBL23692714 | 0.80 | PTK6 (0.34) | PTK6TP53MAPT | |
| SCHEMBL30098618 | 0.80 | PTK6 (0.34) | PTK6TP53MAPT | |
| SCHEMBL29262439 | 0.80 | GRM1 (0.46) | GRM1GRM4CCR2KCNH2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295123-A1 | NOVEL IMIDAZOLE-PYRAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4208454-A1 | IMIDAZOLE-PYRAZOLE DERIVATIVES WITH ANTI-BACTERIAL PROPERTIES | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022049011-A1 | IMIDAZOLE-PYRAZOLE DERIVATIVES WITH ANTI-BACTERIAL PROPERTIES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295123-A1 | NOVEL IMIDAZOLE-PYRAZOLE DERIVATIVES | CYP3A7, NISCH, ARG1 | GRM1 4458/4885GRM4 4658/4885PTK6 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.